{"id":62285,"date":"2012-12-05T15:55:38","date_gmt":"2012-12-05T15:55:38","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/new-clinical-data-highlighting-foundation-medicines-next-generation-sequencing-analysis-in-breast-cancer-to-be.php"},"modified":"2012-12-05T15:55:38","modified_gmt":"2012-12-05T15:55:38","slug":"new-clinical-data-highlighting-foundation-medicines-next-generation-sequencing-analysis-in-breast-cancer-to-be","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/new-clinical-data-highlighting-foundation-medicines-next-generation-sequencing-analysis-in-breast-cancer-to-be.php","title":{"rendered":"New Clinical Data Highlighting Foundation Medicine\u2019s Next-Generation Sequencing Analysis in Breast Cancer to be &#8230;"},"content":{"rendered":"<p><p>      CAMBRIDGE, Mass.--(BUSINESS WIRE)--    <\/p>\n<p>            Foundation Medicine, Inc., a molecular information      company that brings comprehensive cancer genomic analysis to      routine clinical care, today announced that new data from its      collaborations with multiple academic medical center research      groups will be presented at the 2012 CTRC-AACR San Antonio      Breast Cancer Symposium (SABCS) taking place December 4-8,      2012 in San Antonio, Texas. These presentations highlight      Foundation Medicines targeted next-generation sequencing      platform for comprehensive molecular profiling in cancer.    <\/p>\n<p>      Foundation Medicines core commitment is towards a      transformation in cancer care, where each patients treatment      is informed by a deep understanding of the genomic and other      molecular changes that contribute to their disease, said      Gary Palmer, M.D., J.D., senior vice president, medical      affairs, Foundation Medicine. These new data, presented with      our collaborators at SABCS, provide oncology thought leaders      with new, deeper insight into the molecular drivers of breast      cancer. We feel these findings will accelerate advances in      patient care.    <\/p>\n<p>      The schedule for Foundation Medicines presentations is as      follows:    <\/p>\n<p>            Date & Time: Wednesday, December 5, 2012 at            5:00 p.m. CT          <\/p>\n<p>            Title: Next-generation sequencing of FFPE breast            cancers demonstrates high concordance with FISH in            calling HER2 amplifications and commonly detects other            clinically relevant genomic alterations          <\/p>\n<p>            Abstract: PD02-07          <\/p>\n<p>            Session: Poster Discussion 2  HER2          <\/p>\n<p>            Location: Ballroom B          <\/p>\n<p>            Presenter: Doron Lipson, Foundation Medicine            (research in collaboration with Albany Medical College)          <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Go here to see the original: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/clinical-data-highlighting-foundation-medicine-133000303.html;_ylt=A2KJjalqbr9QU1MAxQn_wgt.\" title=\"New Clinical Data Highlighting Foundation Medicine\u2019s Next-Generation Sequencing Analysis in Breast Cancer to be ...\">New Clinical Data Highlighting Foundation Medicine\u2019s Next-Generation Sequencing Analysis in Breast Cancer to be ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new data from its collaborations with multiple academic medical center research groups will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8, 2012 in San Antonio, Texas. These presentations highlight Foundation Medicines targeted next-generation sequencing platform for comprehensive molecular profiling in cancer.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/new-clinical-data-highlighting-foundation-medicines-next-generation-sequencing-analysis-in-breast-cancer-to-be.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-62285","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/62285"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=62285"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/62285\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=62285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=62285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=62285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}